|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125749 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-30 18:29:49 |
|
注册时间: Date of Registration: |
2026-05-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
宿主适应性进化调控罗伊氏乳杆菌消化道定植能力的机制研究 |
|
Public title: |
Mechanistic Study of How Host-adaptive Evolution Regulates the Gut Colonization of Limosilactobacillus reuteri |
|
注册题目简写: |
具有长期定植人消化道潜力的一株罗伊氏乳杆菌的研究 |
|
English Acronym: |
A Limosilactobacillus reuteri Strain with Long-Term Colonization Potential in Human Gastrointestinal Tract |
|
研究课题的正式科学名称: |
宿主适应性进化调控罗伊氏乳杆菌消化道定植能力的机制研究 |
|
Scientific title: |
Mechanistic Study of How Host-adaptive Evolution Regulates the Gut Colonization of Limosilactobacillus reuteri |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨镒 |
研究负责人: |
李福勇 |
|
Applicant: |
Yi Yang |
Study leader: |
Fuyong Li |
|
申请注册联系人电话: Applicant telephone: |
+86 188 0572 8191 |
研究负责人电话:
Study leader's |
+86 131 7360 6659 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yiyang_cas@zju.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
fuyong@zju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市西湖区余杭塘路866号 |
研究负责人通讯地址: |
浙江省杭州市西湖区余杭塘路866号 |
|
Applicant address: |
866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang |
Study leader's address: |
866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang |
|
申请注册联系人邮政编码: Applicant postcode: |
310058 |
研究负责人邮政编码: Study leader's postcode: |
310058 |
|
申请人所在单位: |
浙江大学动物科学学院 |
||
|
Applicant's institution: |
College of Animal Sciences, Zhejiang University |
||
|
研究负责人所在单位: |
浙江大学动物科学学院 |
||
|
Affiliation of the Leader: |
College of Animal Sciences, Zhejiang University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
浙大生食伦审 [2025] 14号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江大学生物系统工程与食品科学学院科技伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee for Science and Technology, College of Biosystems Engineering and Food Science |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-18 00:00:00 | ||
|
伦理委员会联系人: |
陈幸祎 |
||
|
Contact Name of the ethic committee: |
Xingyi Chen |
||
|
伦理委员会联系地址: |
浙江省杭州市西湖区余杭塘路866号 |
||
|
Contact Address of the ethic committee: |
866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 88982726 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
sgspkjll@zju.edu.cn |
|
研究实施负责(组长)单位: |
浙江大学 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhejiang University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市西湖区余杭塘路866号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
浙江大学高层次人才启动基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Zhejiang University Start-up Fund for High-level Talents |
||||||||||||||||||||||
|
研究疾病: |
NA |
||||||||||||||||||||||
|
Target disease: |
NA |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
验证罗伊氏乳杆菌PB-W1和其自然突变株P1D42-6在人体消化道内定植能力的差异,为筛选具有人体定植潜力的益生菌菌株提供理论依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To compare the colonization capacity of Lactobacillus reuteri PB-W1 and its natural mutant P1D42-6 in the human gastrointestinal tract, thereby providing theoretical basis for screening effective probiotic strains with persistent colonization potential in human. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
招募年龄为18–45岁、体质指数(BMI)介于18.5–28 kg/m2之间的健康受试者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Healthy volunteers (n ≥ 10), aged 18-45 years with a body mass index (BMI) between 18.5 and 28 kg/m2 will be recruited. |
||||||||||||||||||||||
|
排除标准: |
1. 具有长期胃肠道疾病(如炎症性肠病、乳糜泻)、糖尿病、心血管疾病、癌症或其他炎症性疾病病史者; 2. 长期服用泻药、降糖药、降压药、降脂药或抗炎药者; 3. 妊娠试验呈阳性(由筛查访视中的尿样检测确定)、或自述处于哺乳期或绝经期的女性; 4. 排便频率少于每日一次者; 5. 每周饮酒超过7次、吸烟(包括咀嚼烟草)或使用非法药物及大麻者; 6. 每周剧烈运动时间超过5小时者; 7. 对任何食物或试验饮食成分存在过敏或不耐受者; 8. 素食者或严格素食者; 9. 在开始试验前3个月内使用过抗生素者; 10. 在开始试验前使用过益生菌、益生元、膳食纤维、omega-3脂肪酸或草本补充剂者(若受试者使用过上述补充剂但符合其他条件,可选择进行为期四周的洗脱期后再参与研究); 11. 粪便中罗伊氏乳杆菌(Lactobacillus reuteri)细胞含量超过10^4个/克。在实验进行期间,受试者不应服用抗生素和补充益生菌产品,不建议食用酸奶及发酵制品。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria are as follows: (1) History of chronic gastrointestinal disorders (e.g., inflammatory bowel disease, celiac disease), diabetes, cardiovascular disease, cancer, or other systemic inflammatory conditions. (2) Long-term use of medications, including laxatives, hypoglycemics, antihypertensives, lipid-lowering agents, or anti-inflammatories. (3) Pregnancy (confirmed by urinalysis at screening), lactation, or postmenopausal status. (4) Defecation frequency of less than once per day. (5) Excessive alcohol consumption (>7 drinks/week), tobacco use, or use of illicit drugs. (6) High levels of vigorous exercise (>5 hours/week). (7) Known allergies or intolerances to any study product components. (8) Adherence to a vegetarian or vegan diet. (9) Antibiotic use within the 3 months preceding the study. (10) Recent use of probiotics, prebiotics, or specific dietary supplements (a 4-week washout period may be permitted for otherwise eligible candidates). Additionally, potential subjects will be screened, and those with baseline fecal L. reuteri levels exceeding 10? CFU/g will be excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2027-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病历记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |